Teva Has A New Near-Term Opportunity With Subcutaneous Risperidone

 
• By Jessica Merrill

A Phase III trial for an extended-release subcutaneously administered version of the antipsychotic risperidone was positive in patients with schizophrenia.

Subcutaneous injection
Teva hopes to bring a subcutaneous risperidone to market • Source: Shutterstock

More from Clinical Trials

More from R&D